Literature DB >> 16626333

Modelling germline mosaicism and different new mutation rates simultaneously for appropriate risk calculations in families with Duchenne muscular dystrophy.

C Fischer1, W Gross, J Krüger, M Cremer, F Vogel, T Grimm.   

Abstract

For several genetic diseases two biological phenomena have been recognised as important: germline mosaicism; and different new mutation rates in males and females depending on mutation type. Both principles have been investigated separately and their influence on risk estimation in families has been exemplified in the literature. The aim of this paper is to present a general model that includes mosaicism and different new mutation rates. Mosaicism is introduced by defining additional alleles at the disease locus in combination with adapted segregation rules. Taking Duchenne muscular dystrophy as an example, we derive the conditions which have to be fulfilled for a population in mutation selection equilibrium. Our approach describes the model at the population level and not in individual subjects. This has the advantage of being able to use well known algorithms for the calculation of likelihoods in pedigrees, and to include additional diagnostic information such as marker genotypes and carrier deletion test results. We demonstrate the impact of the new model on a typical pedigree. In families where the patient is not available, the distinction between point mutations and deletions is important, since often molecular diagnostic tests for females can only screen for deletions. Negative deletion test results can now be included in the risk calculations.

Entities:  

Mesh:

Year:  2006        PMID: 16626333     DOI: 10.1111/j.1469-1809.2005.00226.x

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  1 in total

1.  Risk assessment and genetic counseling in families with Duchenne muscular dystrophy.

Authors:  Tiemo Grimm; Wolfram Kress; Gerhard Meng; Clemens R Müller
Journal:  Acta Myol       Date:  2012-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.